$KE

Kimball Solutions’s (NASDAQ:KE) Q2 CY2026 Earnings Results: Revenue In Line With Expectations But Stock Drops

Kimball Solutions (NASDAQ:KE) reported Q2 CY2026 revenue of $371.6 million, down 2.3% year on year and in line with Wall Street estimates, while full-year revenue guidance of $1.55 billion at the midpoint was about 1% above analysts’ expectations. Non-GAAP adjusted EPS was -$0.01, missing consensus, and the stock fell 7.3% to $23.32.

Original reporting
Published Aug 12, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Kimball Solutions’s (NASDAQ:KE) Q2 CY2026 Earnings Results: Revenue In Line With Expectations But Stock Drops — source image
Decision brief

The 30-second read

$KEBearishMed
01

Why it matters

Q2 CY2026 results were mixed: revenue met expectations but declined YoY, adjusted EPS missed, and the stock sold off sharply. Full-year revenue guidance slightly beat expectations and operating margin improved, but the EPS miss keeps near-term risk elevated.

02

Market read

This is a single-name earnings reaction with concrete datapoints (revenue, EPS, guidance, margin) and an immediate price move, useful for short-term positioning around margin and EPS trajectory.

03

What to watch

The article notes EPS declines over 5 years and attributes differences to interest/taxes plus buybacks; traders may want to separate one-off financing/tax effects from underlying operating earnings power.

Relevance 8/10Novelty 6/10Timing: after-hours/next-session reaction to Q2 results (stock down 7.3% to $23.32 immediately)

Background

Kimball Solutions is a global electronics contract manufacturer serving automotive, medical, and industrial markets.

Company-level read

Ticker impact

$KEBearishMedium confidence
Context

Kimball Solutions reported Q2 CY2026 revenue of $371.6M in line with estimates, but adjusted EPS missed at -$0.01 and shares fell 7.3%.

Expected impact

Bearish near-term reaction likely persists until investors get clearer evidence on margin durability and EPS trajectory.

Evidence & confidence

The article provides the key earnings datapoints (revenue, guidance midpoint, adjusted EPS miss) and a same-session stock drop, which together define the immediate repricing risk.

Market effects

Signals continued pressure on industrial electronics contract manufacturers where revenue growth is sluggish and profitability is still modest.

No specific regional demand or macro linkage provided in the article.

No explicit global supply-chain or international demand shock described.

Counterpoint

Full-year revenue guidance at the midpoint is 1% above analysts’ estimates, and operating margin improved to 7.8%, which could support a rebound if investors focus on margin progress over EPS timing.

Key entities

  • Kimball Solutions

    Reported Q2 CY2026 revenue of $371.6M, adjusted EPS of -$0.01, and operating margin of 7.8%, with shares down 7.3% after results.

Related articles

$KEHighAI 9/10

Kimball Electronics, Inc. (KE): Results of Operations and Financial Condition

Kimball Electronics, Inc. (KE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit9918k6302026q410k.htm KIMBALL ELECTRONICS, INC. EX-99.1 Document Exhibit 99.1 KIMBALL ELECTRONICS REPORTS Q4 RESULTS; COMPANY PROVIDES GUIDANCE FOR FISCAL 2027 HIGHLIGHTED BY ORGANIC SALES GROWTH AND ACCRETIVE IMPACT OF THE HELVOET ACQUISITION JASPER, Ind., Augus

$KEMedAI 8/10

Kimball Electronics (Nasdaq: KE) said it acquired Helvoet Polymer Technologies B.V., a Europe/India medical CDMO

Kimball Electronics (Nasdaq: KE) said it acquired Helvoet Polymer Technologies B.V., a Europe/India medical CDMO for microfluidics, diagnostics, and drug delivery, for €90m (~$103m) excluding adjustments. The deal is ~9x Helvoet 2026E adjusted EBITDA, expected accretive to fiscal 2027 adjusted earnings and to grow Kimball’s medical sales in the low double digits. Helvoet 2025 revenue was ~$56m.

$KEMedAI 8/10

Kimball Electronics, Inc.: Kimball Electronics Acquires European-Based Medical CDMO, Helvoet Polymer Technologies B.V.

Kimball Electronics (Nasdaq: KE) said it acquired Europe-based medical CDMO Helvoet Polymer Technologies B.V. for €90m (~$103m, excluding adjustments), about 9x estimated calendar 2026 adjusted EBITDA. The deal adds Europe and India capacity, is expected to be accretive to fiscal 2027 adjusted earnings, and should grow Kimball’s medical sales in the low double digits.

$VRTMed

Vertiv, Atkore, and Kimball Electronics Shares Are Falling, What You Need To Know

Shares of Vertiv, Atkore, and Kimball Electronics fell after the May jobs report pushed the 30-year Treasury yield above 5%, raising financing costs for grid, data center power, and industrial electrification projects. The report said AI data center orders stayed strong, but higher long-term rates could lengthen order cycles. Vertiv fell 4.9%, Atkore 3.8%, and Kimball Electronics 5.1% (to $24.92).